Clinical Trial

A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objectives of this trial are to investigate safety, tolerability of alternative dose titration strategies and pharmacokinetics (PK) of BI 3034701 in participants with overweight / obesity and at least one weight related co-morbidity following subcutaneous administration.
Trial Details
NCT Number NCT07754474
Lead Sponsor Boehringer Ingelheim
Conditions Overweight, Obesity
Enrollment 35 participants
Start Date 2026-09-01
Primary Completion 2027-01-17 (estimated)
Study Completion 2027-01-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-10